Alumis Inc
ALMS26.190USD
-0.150-0.57%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
2.73BValor de mercado
PerdaP/L TTM
Mais detalhes de Alumis Inc Empresa
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of ESK-001 for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and Parkinson’s Disease. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
Informações de Alumis Inc
Código da empresaALMS
Nome da EmpresaAlumis Inc
Data de listagemJun 28, 2024
CEOBabler (Martin)
Número de funcionários168
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 28
Endereço280 East Grand Avenue
CidadeSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94080
Telefone16502316625
Sitehttps://www.alumis.com/
Código da empresaALMS
Data de listagemJun 28, 2024
CEOBabler (Martin)
Executivos da empresa Alumis Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Martin Babler
Mr. Martin Babler
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
106.45K
--
Mr. Mark Bradley
Mr. Mark Bradley
Chief Development Officer
Chief Development Officer
48.73K
+26750.00%
Mr. Derrick Richardson
Mr. Derrick Richardson
Senior Vice President - People and Culture
Senior Vice President - People and Culture
42.80K
+42800.00%
Mr. John R. Schroer
Mr. John R. Schroer
Chief Financial Officer
Chief Financial Officer
28.00K
+28000.00%
Dr. Jorn Drappa, M.D., Ph.D.
Dr. Jorn Drappa, M.D., Ph.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
25.45K
+25450.00%
Mr. Patrick (Pat) Machado, J.D.
Mr. Patrick (Pat) Machado, J.D.
Independent Director
Independent Director
7.06K
+7064.00%
Dr. David M. Goldstein, Ph.D.
Dr. David M. Goldstein, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Roy C. Hardiman, J.D.
Mr. Roy C. Hardiman, J.D.
Chief Business and Strategy Officer
Chief Business and Strategy Officer
--
--
Ms. Sara Klein
Ms. Sara Klein
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
--
--
Dr. Srinivas Akkaraju, M.D., Ph.D.
Dr. Srinivas Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Martin Babler
Mr. Martin Babler
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
106.45K
--
Mr. Mark Bradley
Mr. Mark Bradley
Chief Development Officer
Chief Development Officer
48.73K
+26750.00%
Mr. Derrick Richardson
Mr. Derrick Richardson
Senior Vice President - People and Culture
Senior Vice President - People and Culture
42.80K
+42800.00%
Mr. John R. Schroer
Mr. John R. Schroer
Chief Financial Officer
Chief Financial Officer
28.00K
+28000.00%
Dr. Jorn Drappa, M.D., Ph.D.
Dr. Jorn Drappa, M.D., Ph.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
25.45K
+25450.00%
Mr. Patrick (Pat) Machado, J.D.
Mr. Patrick (Pat) Machado, J.D.
Independent Director
Independent Director
7.06K
+7064.00%
Detalhamento da receita
FY2025Q3
FY2025Q2
FY2025Q1
Os dados relevantes ainda não foram divulgados pela empresa.
Por RegiãoUSD
Nome
Receita
Proporção
United States
2.07M
0.00%
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: qua, 4 de fev
Atualizado em: qua, 4 de fev
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Foresite Capital Management, LLC
13.27%
Ayur Maya Capital Management Company, L.P.
12.41%
Samsara BioCapital, LLC
5.20%
VenBio Partners LLC
3.79%
The Vanguard Group, Inc.
3.36%
Outro
61.97%
Investidores
Investidores
Proporção
Foresite Capital Management, LLC
13.27%
Ayur Maya Capital Management Company, L.P.
12.41%
Samsara BioCapital, LLC
5.20%
VenBio Partners LLC
3.79%
The Vanguard Group, Inc.
3.36%
Outro
61.97%
Tipos de investidores
Investidores
Proporção
Private Equity
32.11%
Investment Advisor
11.33%
Hedge Fund
9.51%
Venture Capital
7.36%
Investment Advisor/Hedge Fund
5.96%
Research Firm
0.67%
Individual Investor
0.66%
Bank and Trust
0.07%
Insurance Company
0.02%
Outro
32.32%
Participação acionária institucional
Atualizado em: seg, 8 de dez
Atualizado em: seg, 8 de dez
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
211
79.11M
81.97%
+900.81K
2025Q3
210
78.21M
82.24%
-347.38K
2025Q2
186
78.54M
55.16%
+26.45M
2025Q1
129
40.48M
86.71%
-471.52K
2024Q4
110
40.33M
76.60%
+5.09M
2024Q3
85
35.23M
67.43%
+3.39M
2024Q2
30
30.28M
0.00%
+30.28M
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Foresite Capital Management, LLC
10.61M
10.91%
+580.09K
+5.79%
Nov 21, 2025
Ayur Maya Capital Management Company, L.P.
15.14M
15.57%
-1.00
-0.00%
Sep 30, 2025
Samsara BioCapital, LLC
5.13M
5.28%
+333.62K
+6.95%
Nov 20, 2025
VenBio Partners LLC
4.62M
4.75%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
4.03M
4.15%
+625.40K
+18.37%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
3.79M
3.9%
-17.42K
-0.46%
Sep 30, 2025
Nextech Invest, Ltd.
2.92M
3%
--
--
Sep 30, 2025
Cormorant Asset Management, LP
2.15M
2.21%
--
--
Sep 30, 2025
SR One Capital Management, LP
1.96M
2.02%
--
--
Sep 30, 2025
OrbiMed Advisors, LLC
1.93M
1.98%
--
--
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
ProShares Ultra Nasdaq Biotechnology
0.09%
iShares Micro-Cap ETF
0.05%
Invesco Nasdaq Biotechnology ETF
0.05%
iShares Biotechnology ETF
0.03%
iShares Russell 2000 Value ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.03%
ProShares Hedge Replication ETF
0.02%
iShares Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Proshares Ultra Russell 2000
0.01%
Ver Mais
ProShares Ultra Nasdaq Biotechnology
Proporção0.09%
iShares Micro-Cap ETF
Proporção0.05%
Invesco Nasdaq Biotechnology ETF
Proporção0.05%
iShares Biotechnology ETF
Proporção0.03%
iShares Russell 2000 Value ETF
Proporção0.03%
Invesco RAFI US 1500 Small-Mid ETF
Proporção0.03%
ProShares Hedge Replication ETF
Proporção0.02%
iShares Russell 2000 ETF
Proporção0.01%
ProShares UltraPro Russell2000
Proporção0.01%
Proshares Ultra Russell 2000
Proporção0.01%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
